Article
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
Targeted oncology - 1 May 2024
Basso Michele, Signorelli Carlo, Calegari Maria Alessandra, Lucchetti Jessica, Zurlo Ina Valeria, Dell'Aquila Emanuela, Arrivi Giulia, Zoratto Federica, Santamaria Fiorenza, Saltarelli Rosa, Trovato Giovanni, Caira Giulia, Angotti Lorenzo, Schirripa Marta, Anghelone Annunziato, Schietroma Francesco, Chilelli Mario Giovanni, Salvatore Lisa, Pozzo Carmelo, Tortora Giampaolo
Abstract excerpt
BACKGROUND: There are few molecular markers driving treatment selection in later lines of treatment for advanced colorectal cancer patients. The vast majority of patients who progress after first- and second-line therapy undergo chemotherapy regardless of molecular data. OBJECTIVE: We aimed to assess the prognostic and predictive effects of specific RAS mutations on overall survival of patients receiving...
Topics
Join the communities discussing this publication.